Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival
Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival
复制标题
DOI：
10.1016/s0046-8177(97)90177-5
复制
发表时间：
1997-06-01
期刊：
影响因子：
3.3
通讯作者：
Hennigar, RA
中科院分区：
文献类型：
--
作者：
Gansler, TS;Hardman, W;Hennigar, RA
某些癌症表现出从头脂肪酸生物合成的紊乱，表现为脂肪生成酶脂肪酸合酶（FAS）的过度表达和过度活性。在原发性乳腺癌、前列腺癌和结直肠癌中，FAS升高与肿瘤高分级和晚期的相关性已引起人们对该酶作为预后不良的可能标志物的关注。为了发现FAS在卵巢肿瘤中的类似作用，我们比较了68例卵巢肿瘤中FAS的表达与其组织学特征和临床结果。在48例（71%）病例中观察到FAS的免疫组织化学定位，其中染色为局灶性（定义为1%至20%的细胞中的阳性染色）或多灶性/弥漫性（>20%的细胞中的阳性染色）。大多数（83%）的48例代表类胶质细胞癌，浆液性或粘液性癌和恶性混合苗勒管肿瘤（MMMT）。相比之下，卵巢腺瘤和低恶性潜能肿瘤（LMP）含有很少或没有FAS。FAS表达与组织学诊断之间的相关性具有统计学意义。FAS免疫染色的程度也是预后的预测指标。在所有卵巢恶性肿瘤（包括LMP）患者中，当肿瘤未显示FAS免疫染色或显示FAS免疫染色为局灶性时，中位生存期为64.8个月，而当染色为多灶性/弥漫性时，中位生存期为31.2个月（P = 0.005）。当病例仅限于类胶质瘤、浆液性癌和粘液性癌时，获得了相似的中位生存值。与多灶性/弥漫性表达相比，肿瘤无FAS表达或FAS局灶性表达的患者1年和2年的短期生存率显著较高。因此，FAS升高可作为预测卵巢癌患者临床预后不良的独立标志物。版权所有（C）1997 W.B.桑德斯公司
Certain cancers exhibit derangement of de novo fatty acid biosynthesis, manifested as overexpression and hyperactivity of the lipogenic enzyme fatty acid synthase (FAS). Correlation of elevated FAS with high tumor grade and advanced stage in primary breast, prostate, and colorectal cancers has drawn attention to the enzyme as a possible marker of poor prognosis. To find a similar utility of FAS in ovarian neoplasms, we compared FAS expression in 68 ovarian tumors with their histological features and clinical outcome. Immunohistochemical localization of FAS was observed in 48 (71%) cases in which staining was either focal (defined as positive staining in 1% to 20% of cells) or multifocal/diffuse (positive staining in >20% of cells). Most (83%) of the 48 cases were represented by endometrioid, serous, or mucinous carcinomas and malignant mixed mullerian tumors (MMMTs). In contrast, ovarian adenomas and tumors of low malignant potential (LMPs) contained little or no FAS. Association between FAS expression and histological diagnosis was statistically significant. The extent of FAS immunostaining was also predictive of prognosis. Among all patients with ovarian malignancies (including LMPs), median survival was 64.8 months, when their tumors exhibited no or focal immunostaining for FAS, as opposed to 31.2 months, when staining was multifocal/diffuse (P = .005). Similar median survival values were obtained when cases were limited to endometrioid, serous, and mucinous carcinomas. Short-term survival at 1 and 2 years was significantly higher in patients whose tumors showed no or focal expression of FAS compared with multifocal/diffuse expression. Thus, elevated FAS may serve as an independent marker for predicting poor clinical outcome in patients with ovarian cancer. Copyright (C) 1997 by W.B. Saunders Company.